JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
Tweet Send to a Friend
JPMorgan analyst Hardik Parikh reiterated an Overweight rating and {REMOVEPT} price target on Viking Therapeutic (NASDAQ: VKTX).The analyst comments "VKTX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




